Holen Sie sich die Stockscreener-App
22.88
0.65%
-0.1344
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Highs Report: Is Travere Therapeutics Inc subject to activist investor interestDay Trade & Free Long-Term Investment Growth Plans - خودرو بانک
Institution Moves: What is Travere Therapeutics Incs debt to equity ratioGDP Growth & Stock Market Timing Techniques - خودرو بانک
Aug Highlights: How liquid is Travere Therapeutics Inc stockJuly 2025 Price Swings & Stock Market Timing Techniques - خودرو بانک
Institution Moves: Whats the outlook for Travere Therapeutics Incs sectorWeekly Risk Summary & Fast Entry and Exit Trade Plans - خودرو بانک
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA - MSN
Travere Therapeutics (NASDAQ:TVTX) Shares Down 4.8%Should You Sell? - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Sold by Woodline Partners LP - MarketBeat
Wells Fargo & Company Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00 - MarketBeat
Polar Asset Management Partners Inc. Invests $304,000 in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS (NASDAQ:TVTX) - Seeking Alpha
HC Wainwright Reaffirms Buy Rating for Travere Therapeutics (NASDAQ:TVTX) - MarketBeat
TVTX: Stifel Raises Price Target to $25, Maintains Hold Rating | TVTX Stock News - GuruFocus
Travere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 11, 2025 - BioSpace
Travere Therapeutics, Inc. $TVTX Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Travere Therapeutics (TVTX) Stock Decline Amid Market Activity - GuruFocus
Wells Fargo Raises Price Target for Travere Therapeutics (TVTX) to $35.00 | TVTX Stock News - GuruFocus
H.C. Wainwright reiterates buy rating on Travere Therapeutics stock By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside - Insider Monkey
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? - Yahoo Finance
FDA Drops Advisory Committee for Travere’s FILSPARI Review - MSN
Analysts Set Travere Therapeutics, Inc. (NASDAQ:TVTX) Target Price at $33.43 - MarketBeat
Travere rises as FDA says no AdCom required for Filspari label expansion - MSN
Travere Therapeutics stock hits 52-week high at 25.33 USD - Investing.com India
Top 4% Biotech Hits Three-Year High On An FDA Surprise - Investor's Business Daily
Travere Shares Are Trading Higher Wednesday: What's Going On? - Benzinga
Travere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical Results - Yahoo Finance
TVTX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus
Travere: No AdCom, No ProblemTargeting Big Revenues With FSGS Approval (NASDAQ:TVTX) - Seeking Alpha
Investors Buy Large Volume of Travere Therapeutics Call Options (NASDAQ:TVTX) - MarketBeat
H.C. Wainwright reiterates Buy rating on Travere Therapeutics stock - Investing.com
FDA no longer requires advisory committee for Travere’s FSGS drug By Investing.com - Investing.com South Africa
Travere Therapeutics stock jumps as FDA cancels advisory committee for Filspari - Investing.com Canada
Travere Therapeutics stock hits 52-week high at 25.33 USD By Investing.com - Investing.com Nigeria
Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High - MSN
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS - BioSpace
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for Filspari® in Focused Segmental Glomerulosclerosis - MarketScreener
Travere Therapeutics (TVTX) Rises as FDA Review Progresses Witho - GuruFocus
Travere Therapeutics provides update on FDA advisory committee meeting for Filspari in FSGS - MarketScreener
FDA no longer requires advisory committee for Travere’s FSGS drug - Investing.com
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application - Stocktwits
Trexquant Investment LP Trims Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Bought by Northern Trust Corp - MarketBeat
Adage Capital Partners GP L.L.C. Grows Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
RSI Crosses Above 30 for Travere Therapeutics Inc. — Reversal in Sight2025 Performance Recap & Safe Capital Allocation Plans - beatles.ru
Quant Models Detect Momentum Reversal in Travere Therapeutics Inc.2025 Major Catalysts & Expert Verified Movement Alerts - beatles.ru
0.94%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):